Business Wire

NY-REMOTE

13.7.2021 14:02:07 CEST | Business Wire | Press release

Share
Remote Raises $150 Million Series B Led By Accel to Power a New, Global Workforce

Remote , a leading HR tech platform and provider of global employer of record services and international contractor management, today announced it has raised a $150 million Series B round led by Accel with participation from existing investors including Sequoia, Index Ventures, Two Sigma, General Catalyst and Day One Ventures, and is now valued at over $1 billion. The new round comes in the midst of a massive transformation of the workforce that has ushered in a new era of remote work and empowered companies to recruit talent from anywhere in the world.

The shift to distributed employment created unprecedented demand for Remote’s services: since their $35 million Series A in November 2020, Remote grew its customer base by 7x and increased its users by more than 10x. Remote’s revenue has grown by 65x over the past year, and employee headcount has gone from 50 to 220 employees working remotely in 45 countries since November 2020. Remote is the only Employer of Record (EOR) that owns 100% of its global infrastructure, has legal entities in more than 50 countries with plans to have fully operational legal entities in more than 80 countries by the end of 2021, and in the rest of the world by the end of 2022.

In conjunction with the funding, Remote is announcing the launch of a first-to-market Global Employee API, that enables HR and payroll companies to leverage Remote’s vertically-integrated global employment capabilities and infrastructure within their own platforms. Remote’s Global Employee API is being used by top Employee Management Platform Rippling to allow customers to compliantly onboard international employees, consolidate domestic and international payroll, and accelerate their global expansion.

"Through our partnership with Remote, Rippling’s clients can hire, onboard, and pay someone anywhere in the world — all through one HR system, with one set of reports and analytics, and with one place to make employee changes, across the globe,” shared Parker Conrad, CEO of Rippling. “We chose to partner with Remote because of their global infrastructure, in-house expertise managing entities all over the world, and their strategy to closely integrate their service with clients' other business systems. Rippling + Remote will give HR leaders assurance that their global teams always meet local tax and labor laws, no matter where they work."

With the new funding, Remote will expand their advisory services to include guidance on global benefits, equity incentive planning, visa and immigration support, employee relocation, and more. Remote plans to build its own financial services infrastructure that will streamline and add transparency and speed to international payroll processes, which at present are reliant on external parties. An evolution of Remote’s vertically integrated infrastructure strategy, their financial services will include instant payouts and stock options payment plans all within the Remote platform.

"Our goal is to remove the barriers to hiring internationally, empower our customers to scale, and provide access to job opportunities all over the world,” said Job van der Voort, CEO of Remote. “Our seasoned team has spent the past year expanding our global infrastructure, to deliver elegant solutions to complex international legal challenges, and with this funding, we will be adding new products, services and partnerships."

“Remote is at the center of a profound shift in the way that companies hire. Their new Global Employee API opens up access to Remote’s robust global employment infrastructure and knowledge map, and will help any HR provider expand internationally at a speed impossible before. Remote’s future vision as a financial services provider will consolidate complicated processes into one trusted platform, and we’re excited to partner with the global leader in the quickly emerging category of remote work,” said Miles Clements, Partner at Accel.

In addition to the upcoming Global Employee API launch, Remote has partnered with Greenhouse, the leading applicant tracking system and recruiting software, to integrate with their robust employee information data and increase the speed and accuracy of Remote customers’ onboarding process.

Hiring internationally has traditionally been a costly and cumbersome process that was largely accessible only to multinational corporations with large HR teams. With Remote, companies can now employ talent around the world through a platform of global payroll, tax, benefits, legal and compliance services. Free for international contractors, with pricing starting at $149 per month for early stage startups, Remote provides an unparalleled level of expertise, IP protection, and cost efficiency to customers and their global workforce.

About Remote

Remote is the leading self-serve global employment platform with the only network of 100% owned legal entities around the world. Remote has synthesized international legal systems into a seamless experience for its customers, enabling them to compliantly employ anyone, anywhere. Remote's Global Employee API makes it possible for HR tech partners to leverage our legal infrastructure for global payroll, benefits and compliance. Founded in 2019 by Job van der Voort (former VP of Product at GitLab) and Marcelo Lebre (former VP of Engineering at Unbabel), Remote is a fully distributed company with employees based all over the world.

For more information, visit www.remote.com .

About Accel

Accel is a global venture capital firm that is the first partner to exceptional teams everywhere, from inception through all phases of private company growth. Atlassian, Braintree, Cloudera, Crowdstrike, DJI, DocuSign, Dropbox, Etsy, Facebook, Flipkart, Freshworks, Jet, Pillpack, Qualtrics, Slack, Spotify, Supercell, Tenable, UiPath, and Venmo are among the companies Accel has backed over the past 35+ years. We help ambitious entrepreneurs build iconic global businesses. For more, visit www.accel.com or www.twitter.com/accel .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye